Revance to Release Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
Revance Therapeutics, Inc. (Nasdaq: RVNC) will announce its third quarter 2022 financial results on November 8, 2022, after market close. A conference call and live webcast are scheduled for 4:30 p.m. ET the same day to discuss the results and provide updates on business and pipeline initiatives. Revance specializes in innovative aesthetic and therapeutic offerings, including the DAXXIFY™ injection and biosimilar development for BOTOX®. The call will be accessible via registration, with a replay available for 30 days post-call.
- Revance is focused on innovative aesthetic and therapeutic products, positioning itself strongly in the market.
- Scheduled financial results and updates may provide insights into business performance and strategic direction.
- None.
Conference Call Scheduled for
To access the call by phone, please use this registration link, and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. A webcast replay will be available in the investor relations section on the company's website for 30 days following the completion of the call. To access the replay, register via the event link to access the webcast and dial in number. The webcast will be available in the investor relations section on the company's website for 90 days following the completion of the call.
About Revance
Revance is a commercial stage biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that elevate patient and physician experiences. Revance’s aesthetics portfolio of expertly created products and services, including DAXXIFY™ (DaxibotulinumtoxinA-lanm) for injection, the RHA® Collection of dermal fillers, and OPUL®, the first-of-its-kind Relational Commerce platform for aesthetic practices, deliver a differentiated and exclusive offering for the company’s elite practice partners and their consumers. Revance has also partnered with Viatris Inc. to develop a biosimilar to BOTOX®, which will compete in the existing short-acting neuromodulator marketplace. Revance’s therapeutics pipeline is currently focused on muscle movement disorders including evaluating DAXXIFY™ in two debilitating conditions, cervical dystonia and upper limb spasticity.
Revance is headquartered in
“Revance” and the Revance logo and OPUL are registered trademarks of
Resilient Hyaluronic Acid® and RHA® are trademarks of
BOTOX® is a registered trademark of
View source version on businesswire.com: https://www.businesswire.com/news/home/20221101005556/en/
Media
sfahy@revance.com
Investors
jessica.serra@revance.com
or
laurence@gilmartinir.com
Source:
FAQ
What date will Revance Therapeutics release its Q3 2022 financial results?
What time is the Revance Therapeutics conference call scheduled?
What are Revance Therapeutics' main products?
Where can I access the conference call for Revance Therapeutics?
